Literature DB >> 16680582

Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE.

Frederic Triponez1, Pierre Goudet, David Dosseh, Patrick Cougard, Catherine Bauters, Arnaud Murat, Guillaume Cadiot, Patricia Niccoli-Sire, Alain Calender, Charles A G Proye.   

Abstract

BACKGROUND: The management of small, nonfunctioning pancreaticoduodenal endocrine tumors (NFPET) in multiple endocrine neoplasia type 1 (MEN1) patients is still controversial. We therefore investigated the effect of surgery on survival and tumor progression in MEN1 patients with NFPET < or = 2 cm by analyzing data from the Groupe des Tumeurs Endocrines (GTE) registry.
MATERIALS AND METHODS: Among 579 MEN1 patients in the registry, 65 had NFPET < or = 2 cm. Fifteen (23%) underwent pancreatectomy, 9 at least segmental pancreatectomies and 6 biopsies or enucleations (the surgery group), and 50 (77%) were followed conservatively (the no surgery group). Age at MEN1 and NFPET diagnosis was similar in both groups, as was size of the primary tumor. Seven (10.8%) patients had metastases. Five metastases were synchronous, and 2 (one in each group) were metachronous. Tumor size was similar in patients with or without metastasis.
RESULTS: There was no perioperative mortality. The average follow-up time after NFPET diagnosis was 6.7 years in the surgery group and 3.3 years in the no surgery group. Three (4.6%) patients died during follow-up, 2 due to NFPET and 1 due to thymus tumor. The 2 patients who died of NFPET had undergone pancreatic surgery at the time of NFPET diagnosis. The 2 groups did not differ significantly with respect to tumor progression [5/15 (33%) vs 6/38 (16%), P = 0.16]. Overall life expectancy of patients with NFPET < or = 2 cm was not different than that of the 229 MEN1 patients in the registry without any pancreaticoduodenal tumor (P = 0.33).
CONCLUSIONS: This study suggests that surgery may not be beneficial for MEN1 patients with NFPET < or = 2 cm.

Entities:  

Mesh:

Year:  2006        PMID: 16680582     DOI: 10.1007/s00268-005-0354-9

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  22 in total

1.  Hospital volume and surgical mortality in the United States.

Authors:  John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

Review 2.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

3.  Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans.

Authors:  D M Kendall; D E Sutherland; J S Najarian; F C Goetz; R P Robertson
Journal:  N Engl J Med       Date:  1990-03-29       Impact factor: 91.245

Review 4.  Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop.

Authors:  B Wiedenmann; R T Jensen; M Mignon; C I Modlin; B Skogseid; G Doherty; K Oberg
Journal:  World J Surg       Date:  1998-03       Impact factor: 3.352

5.  Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1.

Authors:  Laurence Thomas-Marques; Arnaud Murat; Brigitte Delemer; Alfred Penfornis; Catherine Cardot-Bauters; Eric Baudin; Patricia Niccoli-Sire; Damien Levoir; Hélène du Boullay Choplin; Olivier Chabre; Nicolas Jovenin; Guillaume Cadiot
Journal:  Am J Gastroenterol       Date:  2006-02       Impact factor: 10.864

6.  Duodenopancreatic resections in patients with multiple endocrine neoplasia type 1.

Authors:  T C Lairmore; V Y Chen; M K DeBenedetti; W E Gillanders; J A Norton; G M Doherty
Journal:  Ann Surg       Date:  2000-06       Impact factor: 12.969

Review 7.  Exocrine and endocrine pancreatic insufficiency after pancreatic surgery.

Authors:  Stefan Kahl; Peter Malfertheiner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2004-10       Impact factor: 3.043

8.  Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1.

Authors:  Peter Langer; Peter H Kann; Volker Fendrich; Gerd Richter; Saskia Diehl; Matthias Rothmund; Detlef K Bartsch
Journal:  World J Surg       Date:  2004-11-11       Impact factor: 3.352

9.  [Gastrinomas in multiple endocrine neoplasia type-1. A 127-case cohort study from the endocrine tumor group (ETG)].

Authors:  P Goudet; F Peschaud; M Mignon; P Nicoli-Sire; G Cadiot; P Ruszniewski; A Calender; A Murat; E Sarfati; J L Peix; J L Kraimps; J F Henry; P Cougard; C Proye
Journal:  Ann Chir       Date:  2004-04

10.  Cause of death in multiple endocrine neoplasia type 1.

Authors:  S Wilkinson; B T Teh; K R Davey; J P McArdle; M Young; J J Shepherd
Journal:  Arch Surg       Date:  1993-06
View more
  46 in total

Review 1.  Surgical treatment of gastrointestinal neuroendocrine tumors.

Authors:  Volker Fendrich; Detlef K Bartsch
Journal:  Langenbecks Arch Surg       Date:  2011-02-01       Impact factor: 3.445

Review 2.  Contemporary management of nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Rebecca M Minter; Diane M Simeone
Journal:  J Gastrointest Surg       Date:  2011-10-19       Impact factor: 3.452

3.  NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.

Authors:  Matthew H Kulke; Lowell B Anthony; David L Bushnell; Wouter W de Herder; Stanley J Goldsmith; David S Klimstra; Stephen J Marx; Janice L Pasieka; Rodney F Pommier; James C Yao; Robert T Jensen
Journal:  Pancreas       Date:  2010-08       Impact factor: 3.327

4.  Screening of pancreaticoduodenal endocrine tumours in patients with MEN 1: multidetector-row computed tomography vs. endoscopic ultrasound.

Authors:  L Camera; S Paoletta; C Mollica; F Milone; V Napolitano; L De Luca; A Faggiano; A Colao; M Salvatore
Journal:  Radiol Med       Date:  2011-02-01       Impact factor: 3.469

Review 5.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

Review 6.  Recent advances in the diagnosis and management of pancreatic neuroendocrine tumours.

Authors:  Andrew D Hopper; Mustafa Jalal; Alia Munir
Journal:  Frontline Gastroenterol       Date:  2018-10-09

Review 7.  Update on pancreatic neuroendocrine tumors.

Authors:  Logan R McKenna; Barish H Edil
Journal:  Gland Surg       Date:  2014-11

8.  Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.

Authors:  Tetsuhide Ito; Hironobu Sasano; Masao Tanaka; R Yoshiyuki Osamura; Iwao Sasaki; Wataru Kimura; Koji Takano; Takao Obara; Miyuki Ishibashi; Kazuwa Nakao; Ryuichiro Doi; Akira Shimatsu; Toshirou Nishida; Izumi Komoto; Yukio Hirata; Kazuhiko Nakamura; Hisato Igarashi; Robert T Jensen; Bertram Wiedenmann; Masayuki Imamura
Journal:  J Gastroenterol       Date:  2010-02       Impact factor: 7.527

9.  Genetic screening for multiple endocrine neoplasia syndrome type 1 (MEN-1): when and how.

Authors:  Alberto Falchetti
Journal:  F1000 Med Rep       Date:  2010-02-24

Review 10.  Multiple endocrine neoplasia type 1 with upper gastrointestinal hemorrhage and perforation: a case report and review.

Authors:  Ying-Ying Lu; Feng Zhu; Da-Dao Jing; Xie-Ning Wu; Lun-Gen Lu; Gen-Quan Zhou; Xing-Peng Wang
Journal:  World J Gastroenterol       Date:  2013-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.